ES2313985T3 - Imidazoles sutituidos como agonistas o antagonistas de histamina h1 y h3. - Google Patents

Imidazoles sutituidos como agonistas o antagonistas de histamina h1 y h3. Download PDF

Info

Publication number
ES2313985T3
ES2313985T3 ES01973110T ES01973110T ES2313985T3 ES 2313985 T3 ES2313985 T3 ES 2313985T3 ES 01973110 T ES01973110 T ES 01973110T ES 01973110 T ES01973110 T ES 01973110T ES 2313985 T3 ES2313985 T3 ES 2313985T3
Authority
ES
Spain
Prior art keywords
compound
baselineskip
group
lower alkyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01973110T
Other languages
English (en)
Spanish (es)
Inventor
Robert G. Aslanian
Stuart B. Rosenblum
Mwangi Wa Mutahi
Neng-Yang Shih
John J. Piwinski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2313985T3 publication Critical patent/ES2313985T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES01973110T 2000-09-20 2001-09-18 Imidazoles sutituidos como agonistas o antagonistas de histamina h1 y h3. Expired - Lifetime ES2313985T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23404000P 2000-09-20 2000-09-20
US234040P 2000-09-20

Publications (1)

Publication Number Publication Date
ES2313985T3 true ES2313985T3 (es) 2009-03-16

Family

ID=22879630

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01973110T Expired - Lifetime ES2313985T3 (es) 2000-09-20 2001-09-18 Imidazoles sutituidos como agonistas o antagonistas de histamina h1 y h3.

Country Status (14)

Country Link
US (1) US6518287B2 (enExample)
EP (1) EP1318983B1 (enExample)
JP (1) JP2004509870A (enExample)
CN (1) CN1461299A (enExample)
AR (1) AR032895A1 (enExample)
AT (1) ATE411983T1 (enExample)
AU (1) AU2001292723A1 (enExample)
CA (1) CA2421823A1 (enExample)
DE (1) DE60136284D1 (enExample)
ES (1) ES2313985T3 (enExample)
HK (1) HK1052181A1 (enExample)
MX (1) MXPA03002447A (enExample)
MY (1) MY129677A (enExample)
WO (1) WO2002024658A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050090527A1 (en) * 2003-01-28 2005-04-28 Schering Corporation Combination of H1, H3 and H4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
BRPI0514857A (pt) * 2004-09-03 2008-05-06 Celgene Corp composto ou um sal, solvato ou hidrato farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos para inibir a angiogênese, para inibir ou reduzir a polimerização da tubulina ou a estabilidade da tubulina em uma célula, para inibir a atividade de pde4 em uma célula, para inibir atividade do fator-alfa de necrose de tumor (tnf-alfa) em uma célula, para tratar ou melhorar um distúrbio inflamatório, para tratar ou melhorar cáncer, para inibir a proliferação de célula cancerosa, para marcar, bloquear ou destruir a função de vasculatura tumoral, para marcar, bloquear ou destruir o endotélio de vasos tumor, para marcar, bloquear ou destruir a função de vasculatura tumoral e inibir a angiogênese em um tumor e para tratar ou melhorar um distúrbio do sistema nervoso central
JP2009522246A (ja) * 2005-12-30 2009-06-11 ランバクシー ラボラトリーズ リミテッド ムスカリン性レセプターアンタゴニスト
EP2094643B1 (en) 2006-12-01 2012-02-29 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3512084A1 (de) * 1985-04-02 1986-10-09 Ludwig Heumann & Co GmbH, 8500 Nürnberg Guanidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
FR2586562B1 (fr) 1985-09-02 1989-03-10 Inst Nat Sante Rech Med Composition pharmaceutique contenant de l'a-methylhistamine
DE3631334A1 (de) * 1986-09-15 1988-03-17 Heumann Pharma Gmbh & Co Neue imidazolylguanidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB8916947D0 (en) 1989-07-25 1989-09-13 Smith Kline French Lab Medicaments
DK0448765T3 (da) 1990-03-30 1994-09-19 Heumann Pharma Gmbh & Co Anvendelse af guanidinderivater til fremstilling af et lægemiddel med NPY-antagonistisk virkning
GB9115740D0 (en) 1991-07-20 1991-09-04 Smithkline Beecham Plc Medicaments
CA2125964C (en) 1991-12-18 2001-06-19 Neng-Yang Shih Imidazolyl-alkyl-piperazine and -diazepine derivatives as histamine h3 agonists/antagonists
FR2686084B1 (fr) * 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
HUT74386A (en) 1993-11-15 1996-12-30 Schering Corp Phenyl-alkyl imidazoles as h3-receptor antagonists and pharmaceutical compositions containing them
FR2732017B1 (fr) 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
DK1019050T3 (da) 1997-06-24 2002-07-08 Novo Nordisk As Anvendelse af somatostatinagonister og -antagonister til behandling af sygdomme i forbindelse med øjet
US5869479A (en) 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
US6211182B1 (en) * 1999-03-08 2001-04-03 Schering Corporation Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms

Also Published As

Publication number Publication date
HK1052181A1 (zh) 2003-09-05
MY129677A (en) 2007-04-30
EP1318983A2 (en) 2003-06-18
AR032895A1 (es) 2003-12-03
US6518287B2 (en) 2003-02-11
CN1461299A (zh) 2003-12-10
AU2001292723A1 (en) 2002-04-02
US20020103235A1 (en) 2002-08-01
DE60136284D1 (de) 2008-12-04
EP1318983B1 (en) 2008-10-22
WO2002024658A3 (en) 2002-07-11
MXPA03002447A (es) 2003-07-21
ATE411983T1 (de) 2008-11-15
WO2002024658A2 (en) 2002-03-28
CA2421823A1 (en) 2002-03-28
JP2004509870A (ja) 2004-04-02

Similar Documents

Publication Publication Date Title
KR101088247B1 (ko) 크로메인 치환된 벤즈이미다졸 및 이들의 산 펌프억제제로서의 용도
CN113329999B (zh) 具有雄激素受体降解活性的新型取代的喹啉-8-甲腈衍生物及其用途
EP1611123B1 (en) Tie-2 modulators and methods of use
KR100736063B1 (ko) 치환된 피페리딘, 당해 화합물을 함유하는 약제 및 이의제조방법
JP2004502642A (ja) カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
MX2014014961A (es) Compuestos y composiciones que modulan la actividad del receptor del factor de crecimiento epidermico (egfr).
CN102089290A (zh) 用于疾病治疗的三唑衍生物
KR101162047B1 (ko) ＴＡＦＩａ 억제제로서의 이미다졸 유도체
CN101273021A (zh) 选择的cgrp拮抗剂、其制备方法及其作为药物的用途
KR20050085170A (ko) 당뇨병 치료에 유용한 아닐리노피라졸 유도체
TW202110833A (zh) 新穎環狀緩激肽b2受體拮抗劑
CZ20023243A3 (cs) Pyrrolidinové deriváty, způsob jejich výroby, jejich pouľití a farmaceutický prostředek
ES2233708T3 (es) Imidazoles sustituidos como agonistas o antagonistas duales de la histamina h1 y la h3.
JP2007532601A (ja) 選択されたｃｇｒｐ−拮抗薬、その調製方法および薬剤としてのその使用
ES2313985T3 (es) Imidazoles sutituidos como agonistas o antagonistas de histamina h1 y h3.
JP4350948B2 (ja) オキシトシン調節活性を有するピロリジンエステル誘導体
KR100938817B1 (ko) 안지오텐신 ⅱ 작용제로 유용한 삼중고리 화합물
US6528522B2 (en) Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
JP2004509871A (ja) 二重ヒスタミンｈ１およびｈ３のアゴニストまたはアンタゴニストとしての置換イミダゾール
US5032599A (en) N-(pyrrol-l-yl)pyridinamines
TW202110429A (zh) 環狀緩激肽b2受體拮抗劑
US5194618A (en) N-(pyrrol-1-yl)pyridinamines